Skip to Main Content
Leveraged & Inverse ETFs

Direxion Daily LLY Bull 2X ETF

The Direxion Daily LLY Bull 2X ETF seeks daily investment results, before fees and expenses, of 200% of the performance of the common shares of Eli Lilly and Company (NYSE: LLY).

Investing in the funds involves a high degree of risk. Unlike traditional ETFs, or even other leveraged and/or inverse ETFs, these leveraged and/or inverse single-stock ETFs track the price of a single stock rather than an index, eliminating the benefits of diversification. Leveraged and inverse ETFs pursue daily leveraged investment objectives, which means they are riskier than alternatives which do not use leverage. They seek daily goals and should not be expected to track the underlying stock’s performance over periods longer than one day. They are not suitable for all investors and should be utilized only by investors who understand leverage risk and who actively manage their investments. The Funds will lose money if the underlying stock’s performance is flat, and it is possible that the Bull Fund will lose money even if the underlying stock’s performance increases, and the Bear Fund will lose money even if the underlying stock’s performance decreases, over a period longer than a single day. Investing in the Funds is not equivalent to investing directly in LLY.

ELIL

NAV (Net Asset Value)$28.37As of Jun 10, 2026
1 Day NAV change$-0.42(-1.47%)As of Jun 10, 2026
Daily Target+200%
Intra-day ValueELIL.IV
Daily NAV$28.37
Daily Market Price$28.36
Expense Ratio
(gross/net %)
1.31 / 1.07*
Daily Volume50,500
Security Identifier25461A312
Inception DateMar 26, 2025

Operational Updates

  • 03/13/2026
    Direxion to Close ELIS on 4/10/26.
    Read the Press Release.

Documents & Downloads

  • ELIL Fact Sheet (pdf)
  • Direxion ETFs List (pdf)
  • Single Stock ETFs List (pdf)
  • ELIL Prospectus
  • Daily Fund Holdings (csv)

Single Stock Exposure

Eli Lilly and Company is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines in various therapeutic areas, including neuroscience, endocrinology, oncology, cardiovascular diseases, and immunology. Its portfolio encompasses a wide range of prescription drugs, biologics, and animal health products. LLY is registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Information provided to or filed with the Securities and Exchange Commission by Eli Lilly and Company pursuant to the Exchange Act can be located by reference to the Securities and Exchange Commission file number 001-06351 through the Securities and Exchange Commission’s website at www.sec.gov. In addition, information regarding Eli Lilly and Company may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents.

Important Information Regarding ELIL

The Direxion Daily LLY Bull 2X ETF (ELIL) seeks 200% daily leveraged investment results and thus will have an increase of volatility relative to the underlying LLY performance itself. Longer holding periods, higher volatility of LLY and leverage increase the impact of compounding on an investor’s returns. During periods of higher LLY volatility, the volatility of LLY may affect the fund’s performance.

Pricing & Performance

NAV and Market Price information as of 06/10/2026.

ELIL Direxion Daily LLY Bull 2X ETF
Net Asset Value (NAV)
$28.37Nav
$-0.42Change
-1.47%Change
Market Price Closing
$28.36Market
$-0.42Change
-1.46%Change
Premium / Discount
$-0.01Change from Last Day Trading
Premium/Discount tool
Loading chart...
1M3MYTD1Y3Y5Y10YSince
Inception
(03/26/2025)
Expense Ratio*
(Gross / Net%)
ELIL NAV
38.00
4.41
-4.46
77.41
18.50
1.31 / 1.07*
ELIL Market Close
37.55
4.53
-4.34
75.36
17.65
1.31 / 1.07*

As of May 31, 2026

*The Net Expense Ratio includes management fees, other operating expenses and Acquired Fund Fees and Expenses. If Acquired Fund Fees and Expenses were excluded, the Net Expense Ratio  would be 0.95%. The Funds’ adviser, Rafferty Asset Management, LLC (“Rafferty”), has entered into an Operating Expense Limitation Agreement with each Fund. Under the Operating Expense Limitation Agreement, Rafferty has contractually agreed to waive all or a portion of its management fee and/or reimburse a Fund for Other Expenses through September 1, 2027, to the extent that a Fund’s Total Annual Fund Operating Expenses exceed 0.95% of the Fund’s average daily net assets (excluding, as applicable, among other expenses, taxes, swap financing and related costs, acquired fund fees and expenses, dividends or interest on short positions, other interest expenses, brokerage commissions and extraordinary expenses). If these expenses were included, the expense ratio would be higher.

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate. An investor’s shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted. Returns for performance under one year are cumulative, not annualized. For the most recent month-end performance please visit the funds’ website at direxion.com. Short-term performance, in particular, is not a good indication of a fund’s future performance, and an investment should not be made based solely on returns. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. For additional information, see the fund’s prospectus.

Distributions

Record DateEx DatePay DateIncome DividendShort-Term Capital GainLong-Term Capital GainExpand
03/24/202603/24/202603/31/20260.05318
12/23/202512/23/202512/31/20250.13209
12/10/202512/10/202512/17/20250.000002.75962
09/23/202509/23/202509/30/20250.09221
Record Date03/24/2026
Ex Date03/24/2026
Pay Date03/31/2026
Income Dividend0.05318
Short-Term Capital Gain
Long-Term Capital Gain
Record Date12/23/2025
Ex Date12/23/2025
Pay Date12/31/2025
Income Dividend0.13209
Short-Term Capital Gain
Long-Term Capital Gain
Record Date12/10/2025
Ex Date12/10/2025
Pay Date12/17/2025
Income Dividend0.00000
Short-Term Capital Gain2.75962
Long-Term Capital Gain
Record Date09/23/2025
Ex Date09/23/2025
Pay Date09/30/2025
Income Dividend0.09221
Short-Term Capital Gain
Long-Term Capital Gain

Documents

Browse Other Funds

View more of our Leveraged & Inverse ETFs at Direxion. As of June 10, 2026
View All

AI Market Insights

As of June 10, 2026
Regulatory and Policy UncertaintyThe “Most Favored Nation” pricing policy introduces uncertainty for Eli Lilly, potentially impacting pricing strategies and revenue, especially from key drugs like Mounjaro and Zepbound.Source: seekingalpha.com
Growth and Innovation in Weight-ManagementEli Lilly is expanding its weight-management market share through strategic partnerships and innovations, such as a collaboration with Camurus and the development of an oral GLP-1 drug, orforglipron, positioning it against competitors like Novo Nordisk.Sources: fool.com, finance.yahoo.com, tradingview.com
Economic and Legislative ChallengesPotential healthcare reforms and economic slowdown pressures Eli Lilly’s stock valuation, while proposed legislation to ban drug ads could alter marketing strategies, affecting consumer engagement.Sources: finance.yahoo.com, fool.com, seekingalpha.com

The information provided in AI Market Insights above is obtained or derived from sources believed by the investment adviser, Rafferty Asset Management, LLC (“Rafferty”), to be reliable. However, Rafferty does not make any representation or warranty, express or implied, as to the information’s accuracy or completeness, nor does Rafferty recommend that the information serve as the basis of any investment decision.

Subscribe to Newsletters & Operational Updates

Sign up for email and/or text of the important news, including:

  • Fund updates including splits, distributions, launches, and other corporate actions
  • Educational events, such as web seminars and conferences
  • Our latest research and industry trends
Subscribe

Our Latest Insights

Liftoff: SpaceX Goes Public on June 12

“Names like SpaceX don’t list often. The demand for tactical, liquid trading access has been building for years.” – Jake Behan, Head of Capital Markets at Direxion

Learn About Leveraged & Inverse ETFs

Trading is different than investing. Use our insights and educational resources to make sure you’re ready to trade in Direxion’s Leveraged and Inverse ETFs.

an illustration of a book with a graduate cap on to represent the Direxion University

Education Center

Educational materials, videos, and self-paced online training.
illustration of an 'X' with candlestick chart elements over the top

The Xchange Newsletter

Leveraged ETF market trends and trading ideas. Read our latest article and subscribe.
an illustration of a video for Leveraged & Inverse ETF Education

Leveraged & Inverse ETF Videos

Short videos to teach you about our Leveraged & Inverse ETFs.